“We’ve had some idea what TRPA1 might look like, but there’s something elegant and satisfying about obtaining the structure, because seeing really is believing.” The "wasabi receptor" is only about a ...

Scientists at the University of California, San Francisco (UCSF) have managed to resolve the 3D structure, to near-atomic resolution, for the ion channel that has been informally dubbed the wasabi ...

Many TRPA1 agonists are electrophilic compounds that covalently modify reactive cysteine residues on TRPA1, which leads to activation of the channel. Electrophiles can bind through reversible or ...

“A few drugs have been developed that target TRPA1, and in our 3-D structure we can see where one such drug binds,” said Julius. “This provides important insight into how this one major class of drugs ...

Acrid smoke and fresh-chopped onions don’t have much in common – other than evoking an eye-watering urge to run to another room. Remarkably, the irritant chemicals in both smoke and onions – as well ...

We examined whether the loss of transient receptor potential ankyrin 1 (TRPA1), an irritant-sensing ion channel, or TRPA1 antagonist treatment affects the severity inflammation and scarring during ...

Proposed model for how acetic acid might activate the ion channel TRPA1. A new study in the Journal of General Physiology identifies TRPA1 as the sensor in animals responsible for identifying weak ...

Scientists report that two structurally unrelated anti-inflammatory compounds both activate the TRPA1 receptor. One, oleocanthal, is found in extra virgin olive oil while ibuprofen is an over-the ...

Rattlesnakes and vipers have pits on their faces that can sense the body heat of their prey in total darkness. The ability depends on a protein called TRPA1 – in humans, the same protein warns ...

Catnip (Nepeta cataria) may have a euphoric effect on cats, but the plant deters insects by triggering a chemical sensor for irritants, a new study shows.Turnip Towers/Alamy Stock Photo ...

Algomedix Inc. Announces Issuance of U.S. Patent for Novel TRPA1 Modulators Designed to Treat Chronic Pain as Alternatives to Addictive Opioids Company has multiple first-in-class programs ...